BIONEWS
A selective TAOK 1 inhibitor and a broad TAOK family activator give researchers their first reliable way to test whether the protein actually drives Alzheimer's pathology.
Alzheimer's disease affects more than seven million Americans, and the drugs on the market mostly soften its symptoms. A team at Vanderbilt has now built the first reliable chemical handle on a brain protein long implicated in the disease. The compounds are not a treatment, but the missing tools that let researchers finally test whether that protein is a real driver.
The protein is TAOK-1, a kinase in the TAO family that has been linked to Alzheimer's and other neurological disorders for years. TAO kinases help regulate how neurons grow, divide, and rewire, and the three human versions (TAOK-1, TAOK-2, and TAOK-3) have all shown up in genetic and post-mortem studies of neurodegeneration. The problem was never suspicion. It was access. "Alzheimer's is a condition that remains recalcitrant to the scientific community's attempts at developing a cure or preventative treatment," said Daniel Schultz, a former postdoctoral fellow at the Vanderbilt Warren Center for Neuroscience Drug Discovery (WCNDD). Without a compound that could selectively turn TAOK-1 up or down, the field could not cleanly test whether the protein was a cause, a passenger, or noise.
In a paper published Feb. 4 in ACS Chemical Neuroscience and recirculated this week via ScienceDaily, Schultz and colleagues describe two tool compounds. The first, VU6083859, is the first selective TAOK-1 inhibitor. The second, VU6080195, is a pan-TAOK activator that turns on the whole TAO kinase family. Tool compounds are chemicals that raise or lower a target protein's activity so researchers can probe what the protein does. They are often not drug-like enough to give to patients, but they are the standard way to answer causal questions about a target.
Until now, anyone who wanted to ask whether TAOK-1 mattered in Alzheimer's had to settle for blunt instruments. Existing inhibitors hit several kinases at once, so any effect in a cell or animal could not be cleanly tied to TAOK-1. VU6083859 changes that. In the Vanderbilt study, the compound was selective enough to give researchers a clean read on TAOK-1's role in neurons, and VU6080195 gave them a way to ask the opposite question: what happens when the whole TAOK family is pushed into overdrive?
The pull goes beyond Alzheimer's. TAOK-1 and its siblings have been implicated in neurodevelopmental disorders as well, and the lack of selective chemistry has been a bottleneck across that whole corner of brain-disease biology. The Vanderbilt paper frames the work the same way: a research-tool unlock, not a therapy. A secondary write-up at SciTechDaily echoes that read.
The caveats are real. These are research compounds, not drug candidates. Vanderbilt's press release describes WCNDD as a "clinical-stage biotech start-up," but that is the institution's own framing of its drug-discovery arm, and the paper itself does not claim therapeutic readiness. The next step is for outside labs to take VU6083859 and VU6080195 into their own Alzheimer's models and run the causal experiments the field has been waiting to run. If turning TAOK-1 off in those models changes the course of the disease, the protein moves from "implicated" to "driver," and a real drug-discovery program becomes possible. If it does not, the field will finally have an honest answer instead of another decade of suspicion.
The watch item is narrow and concrete: the first independent study using VU6083859 in a validated Alzheimer's model. That is the experiment the Vanderbilt tool compounds make possible, and the one that will decide whether TAOK-1 deserves the attention it has been getting.